Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Palmitoyl Tetrapeptide-7 (Pal-GQPR) is an anti-inflammatory cosmetic peptide that reduces IL-6 and other inflammatory cytokines in skin tissue. It is a key component of Matrixyl 3000. When used alone, it addresses inflammation-driven aging, redness, and skin sensitivity.
Protocol Overview
Compound
Palmitoyl Tetrapeptide-7 (Pal-GQPR / Rigin)
Category
Anti-Inflammatory Cosmetic Peptide
Mechanism
Suppresses interleukin-6 (IL-6) production and reduces inflammatory cytokine cascades in dermal tissue. Decreases chronic micro-inflammation (inflammaging) that accelerates collagen breakdown. Palmitoyl group enhances dermal penetration
Half-Life
Local activity in skin layers
Form
Topical serum or cream
Route
Topical
Frequency
2x daily
Cycle Length
Ongoing
Dosing Protocol
Protocol
Dose
Frequency
Route
Duration
Standard Serum
50-100 ppm
2x daily
Topical
Ongoing
Enhanced (Matrixyl 3000)
Combined with Pal-Tripeptide-1
2x daily
Topical
Ongoing
Sensitive Skin
25-50 ppm
1-2x daily
Topical
Ongoing
Expected Timeline
Week 1-2
Reduction in skin redness and irritation. Anti-inflammatory effects begin.
Week 3-4
Visible reduction in inflammatory redness. Skin texture improving.
Week 5-8
Significant improvement in skin tone evenness. Improved skin barrier function.
